Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 354 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Clinical and Biomarker Assessments Clear all
Completed Phase 2 Interventional Results available

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

NCT00810797
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane, laboratory biomarker analysis, quality-of-life assessment, immunohistochemistry staining method
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 7, 2026, 4:46 AM EDT
Completed Early Phase 1 Interventional

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

NCT00757549
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay, 3'-deoxy-3'-[18F]fluorothymidine, immunohistochemistry staining method, laboratory biomarker analysis, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 7, 2026, 4:46 AM EDT
Completed No phase listed Observational

Evaluation of Vaginal Microbiome as a Biomarker for the Improvement of Vaginal Health in Women With Breast Cancer, ARISE Study

NCT05946668
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Completed No phase listed Observational

Transforming Research and Clinical Knowledge in Traumatic Brain Injury

NCT02119182
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
In-Person Outcome Assessment, Phone Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Blood Draw for Plasma, DNA, Serum, RNA
Behavioral · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 100 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
23
States / cities
San Francisco, California • Denver, Colorado • Englewood, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 7, 2026, 4:46 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Longitudinal Assessment of Cartilage Injury and Remodeling After Anterior Cruciate Ligament Rupture and Reconstruction:

NCT03497780
View directory record Official record
Conditions
ACL - Anterior Cruciate Ligament Rupture, ACL Injury, Healthy
Interventions
Anterior cruciate ligament reconstruction
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 30 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 7, 2026, 4:46 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Biomarkers in Human Synovial Fluid

NCT02664870
View directory record Official record
Conditions
Osteoarthritis
Interventions
Arthroscopy, Arthroplasty
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Terminated Phase 1 Interventional

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

NCT01122888
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Solid Neoplasm, Recurrent Adult Brain Neoplasm
Interventions
Cilengitide, Clinical Observation, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 7, 2026, 4:46 AM EDT
Completed No phase listed Observational

Predicting Disease Progression and/or Recurrence in Cancer

NCT04776837
View directory record Official record
Conditions
Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Esophageal Cancer, Metastatic Cancer, Disease Progression, Survival Analysis
Interventions
Observational Cohort
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder

NCT06415994
View directory record Official record
Conditions
Opioid Use Disorder, Substance-Related Disorders, Pregnancy Related, Narcotic-Related Disorders, Buprenorphine Dependence, Methadone Dependence
Interventions
Buprenorphine or Methadone Treatment, Fetal and Placental MRI, Child Developmental Assessment, Questionnaires, Blood and Placental Samples
Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

NCT02828111
View directory record Official record
Conditions
Basal Cell Carcinomas
Interventions
Patidegib, Vehicle gel
Drug
Lead sponsor
PellePharm, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 7, 2026, 4:46 AM EDT
Active, not recruiting Phase 2 Interventional

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

NCT04597359
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
21 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
345
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 224 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Not listed No phase listed Observational

TR(ACE) Assay Clinical Specimen Study

NCT02934360
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
Interventions
TR(ACE) Assay Testing
Device
Lead sponsor
Biological Dynamics
Industry
Eligibility
21 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Encinitas, California • Oceanside, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 7, 2026, 4:46 AM EDT
Completed Not applicable Interventional

Analysis of Bone Micro-Architecture as a Clinical Biomarker for Image-Based Fracture Risk Estimation.

NCT03463850
View directory record Official record
Conditions
Osteoporosis
Interventions
Dual Energy CT (DECT), DEXA
Radiation
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
60 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Completed No phase listed Observational

Developmental Outcomes

NCT02264808
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
Developmental Outcomes
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Months to 20 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 7, 2026, 4:46 AM EDT
Active, not recruiting Not applicable Interventional

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

NCT06218589
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
Velacur, MRI, Blood sample collection for biomarkers, Liver biopsy
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
2 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease, Prostate Hypertrophy, Prostate Pain, Lower Urinary Tract Symptoms, Urinary Obstruction, Urinary Tract Disease
Interventions
Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 7, 2026, 4:46 AM EDT
Not yet recruiting No phase listed Observational

A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

NCT07814872
View directory record Official record
Conditions
Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Glioma, Ovarian Neoplasms, Stomach Neoplasms
Interventions
Not listed
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
Not listed
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Active, not recruiting Phase 2 Interventional Results available

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

NCT02392429
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chemotherapy, Computed Tomography, Cytarabine, Fluorothymidine F-18, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
11
States / cities
Rochester, Minnesota • St Louis, Missouri • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of a Decision-Support Tool for Blood Biomarker Testing for Alzheimer's Disease in Primary Care

NCT07812337
View directory record Official record
Conditions
Cognitive Abnormality
Interventions
Shared decision-making support tool
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

NCT02717507
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Carvedilol, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 7, 2026, 4:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01886872
View directory record Official record
Conditions
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
65 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
917
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 596 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

NCT00520767
View directory record Official record
Conditions
Primary Systemic Amyloidosis, Light Chain Deposition Disease
Interventions
bortezomib, dexamethasone, melphalan, microarray analysis, flow cytometry, laboratory biomarker analysis, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
7
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 7, 2026, 4:46 AM EDT
Completed No phase listed Observational

Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer

NCT00805688
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Questionnaires, Blood Draws, Pedometer
Behavioral · Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 7, 2026, 4:46 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

NCT07106879
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Interventions
Blood Work
Other
Lead sponsor
Clindove Research LLC
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 7, 2026, 4:46 AM EDT